How much revenue does Themis Medicare make?

Themis Medicare reported 4.00 billion INR in revenue for fiscal year 2025, up 6.2% from 3.77 billion INR in fiscal year 2024. In Q3 2026 revenue was 901.33 million INR.

Where does Themis Medicare make most of its revenue?

India: 82% of revenue by region in fiscal year 2025, followed by Outside India (18%).

What companies are similar to Themis Medicare?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Bharat Parenterals Ltd (BPLPHARMA.BO), Lincoln Pharmaceuticals Limited (LINCOLN.NS), Bafna Pharmaceuticals Limited (BAFNAPH.NS), Kilitch Drugs (India) Limited (KILITCH.NS).

Themis Medicare Limited (THEMISMED.NS) Stock

About Themis Medicare Limited

Themis Medicare Limited, together with its subsidiaries, manufactures and sells pharmaceutical products in India and internationally. It provides active pharmaceutical ingredients (APIs) and formulations used in various therapeutic areas, including analgesic and anti-inflammatory, analgesic and antispasmodic, analgesics, anesthesia, antacid-antiflatulent, anti-fungal, antibiotic, anti-diabetic, an...

At a glance

Themis Medicare reported revenue of 4.00 billion INR for fiscal year 2025, up 6.2% from fiscal year 2024, and net income of 298.33 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 901.33 million INR, down 3.9% from a year before. India was its largest region in fiscal year 2025, with 82% of revenue.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.